“A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland”, Swiss Med Wkly, vol. 155, no. 1, p. 3777, Jan. 2025, doi: 10.57187/s.3777.